Barclays’s Celldex Therapeutics CLDX Stock Holding History

Barclays’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.73M	Buy	+53,300	New	+$2.04M	﹤0.01%	2689
2018 Q2	–	Sell	-5,867	Closed	-$205K	–	6994
2018 Q1	$205K	Buy	+5,867	New	+$227K	﹤0.01%	4810
2015 Q2	–	Sell	-1,713	Closed	-$694K	–	7027
2015 Q1	$694K	Sell	1,713 -3,434	-67%	-$1.23M	﹤0.01%	3296
2014 Q4	$1.39M	Buy	+5,147	New	+$1.28M	﹤0.01%	2874
2014 Q1	–	Sell	-8,333	Closed	-$3M	–	7578
2013 Q4	$3M	Buy	8,333 +4,293	+106%	+$1.65M	﹤0.01%	2268
2013 Q3	$2.12M	Buy	+4,040	New	+$1.39M	﹤0.01%	2504

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return

Barclays's CLDX Position: Q3 2026 in Review

Barclays increased its Celldex Therapeutics (CLDX) stake by 583% in Q3 2026, buying an estimated $3.36M and bringing the position to 102,996 shares worth $3.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

Barclays first reported a position in CLDX in Q2 2013 and has held it in 51 quarters since. The position peaked at $7.04M in Q1 2022. 108 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

Barclays held 102,996 shares of Celldex Therapeutics worth $3.34M as of Q3 2026.
Barclays bought 87,909 Celldex Therapeutics shares in Q3 2026, an estimated $3.36M.
Celldex Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2271 holding.
Barclays first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 51 quarters since.
Barclays's Celldex Therapeutics position peaked at $7.04M in Q1 2022.
108 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.